Steroidal neuromuscular blocking agent encapsulation

"Steroidal neuromuscular blocking agent encapsulation" refers to the **process** by which certain reversal agents—most notably **sugammadex**, a modified gamma-cyclodextrin—bind and inactivate aminosteroidal nondepolarizing neuromuscular blockers such as rocuronium, vecuronium, and pancuronium. This is achieved through tight 1:1 molecular encapsulation that prevents these drugs from interacting with nicotinic acetylcholine receptors at the neuromuscular junction. The result is rapid reversal of drug-induced muscle paralysis without cholinergic side effects. This process does not describe an endogenous biological molecule or therapeutic target but rather an exogenous pharmacological mechanism used perioperatively for patient recovery from anesthesia-induced paralysis. While highly specific for steroidal NMBAs, high concentrations of unbound sugammadex can weakly interact with other anesthetic drugs such as propofol; however, this has limited clinical significance under normal dosing conditions.[2][6] **Note:** This entry describes a *drug-drug interaction mechanism*, not an actual molecular target like a receptor or enzyme. Therefore, *is_target = false* and *is_incorrect = true* because "Steroidal neuromuscular blocking agent encapsulation" is not itself considered a canonical therapeutic target but rather describes how one drug class neutralizes another via physical binding/encapsulation.[2][6]

Other names

Sugammadex encapsulation of steroidal neuromuscular blocking agentsEncapsulation of aminosteroidal nondepolarizing neuromuscular blockersCyclodextrin-based reversal of steroidal NMBAs

Encapsulation and inactivation of aminosteroidal nondepolarizing neuromuscular blocking agents by sugammadex at a 1:1 molar ratio, preventing their action at the nicotinic acetylcholine receptor and reversing muscle paralysis[2][6]